Related Experiment Video
Updated: Feb 27, 2026

Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts
Published on: September 20, 2024
Multibiomarker analysis in patients with acute myocardial infarction
Christiana Schernthaner1, Michael Lichtenauer1, Bernhard Wernly1
1Department of Cardiology, Paracelsus Medical University, Salzburg, Austria.
Novel biomarkers like sST2, GDF-15, suPAR, and H-FABP were elevated in acute myocardial infarction (AMI) patients, while fetuin A was lower. These markers correlate with clinical and biochemical factors, offering insights into AMI pathobiology.
Area of Science:
- Cardiology
- Biomarker Discovery
- Pathophysiology
Background:
- Acute myocardial infarction (AMI) involves complex pathobiological pathways.
- Identifying novel biomarkers is crucial for understanding AMI.
- Previous studies have explored various potential indicators of cardiac injury.
Purpose of the Study:
- To investigate the role of novel biomarkers in patients with AMI.
- To compare serum levels of specific biomarkers between AMI patients and controls.
- To analyze correlations between these novel biomarkers and clinical/biochemical parameters.
Main Methods:
- Retrospective analysis of serum levels of soluble suppression of tumorigenicity (sST2), growth-differentiation factor-15 (GDF-15), soluble urokinase plasminogen activator receptor (suPAR), and heart-type fatty acid-binding protein (H-FABP).
- Plasma fetuin A levels were also measured.
- Comparison between patients with ST-elevation myocardial infarction (STEMI) and non-ST-elevation myocardial infarction (NSTEMI) against a control group without coronary artery disease.
- Detailed correlation analysis with clinical and biochemical parameters.
Main Results:
- Significantly higher levels of sST2, GDF-15, suPAR, and H-FABP were observed in both STEMI and NSTEMI patients compared to controls.
- Lower plasma fetuin A levels were detected in AMI patients versus controls.
- Correlation analysis revealed significant associations between these novel biomarkers and ejection fraction, hospital stay duration, creatine kinase, NT-proBNP, hs Troponin T, CRP, and leucocytes.
Conclusions:
- Novel biomarkers sST2, GDF-15, H-FABP, and suPAR are elevated in AMI patients.
- Fetuin A levels are inversely downregulated in AMI patients.
- These biomarkers show significant correlations with clinical and standard biochemical markers, indicating their relevance in AMI.
More Related Videos
10:12A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay
Published on: August 8, 2013
04:41Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
Published on: July 3, 2018
Related Concept Videos
Acute Coronary Syndrome III: Diagnostic Studies
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Myocarditis II: Clinical Features and Diagnostic Tests
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations